NCT05392946 2026-04-21
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT05434689 2026-04-15
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT05560399 2026-01-02
CC-220
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Active not recruiting
NCT05354557 2025-05-18
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05177536 2025-05-13
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
University of Nebraska
Phase 2 Active not recruiting
NCT04998786 2025-04-06
I2D IFM2021_03
Nantes University Hospital
Phase 2 Active not recruiting
NCT04392037 2025-03-28
ICON
Amsterdam UMC, location VUmc
Phase 2 Active not recruiting
NCT04564703 2025-02-25
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
European Myeloma Network B.V.
Phase 2 Active not recruiting